| 2026-09-28 |
Achieve Life Sciences |
Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026 achievelifesciences.com ↗ |
| 2026-06-22 |
Achieve Life Sciences |
Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA achievelifesciences.com ↗ |
| 2026-05-19 |
Achieve Life Sciences |
Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment achievelifesciences.com ↗ |
| 2026-03-26 |
Achieve Life Sciences |
Achieve Life Sciences Announces Publication in Nicotine & Tobacco Research Linking Cytisinicline's Receptor Selectivity to Low Nausea Rates and Favorable Tolerability achievelifesciences.com ↗ |
| 2025-11-06 |
Achieve Life Sciences |
Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program achievelifesciences.com ↗ |
| 2025-11-03 |
Achieve Life Sciences |
Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation achievelifesciences.com ↗ |
| 2025-10-17 |
Achieve Life Sciences |
Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation achievelifesciences.com ↗ |
| 2025-09-22 |
Achieve Life Sciences |
Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline’s Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD achievelifesciences.com ↗ |
| 2025-09-03 |
Achieve Life Sciences |
Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation achievelifesciences.com ↗ |
| 2025-08-07 |
Achieve Life Sciences |
Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program achievelifesciences.com ↗ |
| 2025-06-26 |
Achieve Life Sciences |
Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation achievelifesciences.com ↗ |
| 2025-05-20 |
Achieve Life Sciences |
Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake achievelifesciences.com ↗ |
| 2025-05-13 |
Achieve Life Sciences |
Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program achievelifesciences.com ↗ |
| 2025-04-21 |
Achieve Life Sciences |
Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine achievelifesciences.com ↗ |
| 2025-03-11 |
Achieve Life Sciences |
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program achievelifesciences.com ↗ |
| 2025-01-07 |
Achieve Life Sciences |
Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission achievelifesciences.com ↗ |
| 2024-10-16 |
Achieve Life Sciences |
Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline achievelifesciences.com ↗ |
| 2024-07-31 |
Achieve Life Sciences |
Achieve Life Sciences Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine Dependence achievelifesciences.com ↗ |
| 2024-05-29 |
Achieve Life Sciences |
Achieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes achievelifesciences.com ↗ |
| 2024-05-17 |
Achieve Life Sciences |
Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting achievelifesciences.com ↗ |
| 2024-05-06 |
Achieve Life Sciences |
Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine achievelifesciences.com ↗ |
| 2024-03-20 |
Achieve Life Sciences |
Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting achievelifesciences.com ↗ |
| 2024-02-29 |
Achieve Life Sciences |
Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission achievelifesciences.com ↗ |
| 2023-09-11 |
Achieve Life Sciences |
Achieve Life Sciences Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting achievelifesciences.com ↗ |
| 2023-07-11 |
Achieve Life Sciences |
Achieve Life Sciences Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association (JAMA) achievelifesciences.com ↗ |
| 2023-05-23 |
Achieve Life Sciences |
Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial achievelifesciences.com ↗ |
| 2023-04-20 |
Achieve Life Sciences |
Achieve Life Sciences Announces Positive Phase 2 ORCA-V1 Trial Results Showing Statistically Significant Vaping Cessation Benefit for Participants Treated with Cytisinicline achievelifesciences.com ↗ |
| 2023-03-29 |
Achieve Life Sciences |
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation achievelifesciences.com ↗ |
| 2023-03-08 |
Achieve Life Sciences |
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation achievelifesciences.com ↗ |
| 2023-03-03 |
Achieve Life Sciences |
Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting achievelifesciences.com ↗ |
| 2023-02-07 |
Achieve Life Sciences |
Achieve Life Sciences Announces Last Subject Dosed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation achievelifesciences.com ↗ |
| 2023-01-09 |
Achieve Life Sciences |
Achieve Life Sciences Announces Last Subject Dosed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation achievelifesciences.com ↗ |
| 2022-12-21 |
Achieve Life Sciences |
Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline Formulation achievelifesciences.com ↗ |
| 2022-11-08 |
Achieve Life Sciences |
Achieve Announces Early Completion of Target Enrollment in Cytisinicline e-Cigarette Cessation Trial achievelifesciences.com ↗ |
| 2022-09-27 |
Achieve Life Sciences |
Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation achievelifesciences.com ↗ |
| 2022-06-29 |
Achieve Life Sciences |
Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine e-cigarette Cessation achievelifesciences.com ↗ |
| 2022-06-01 |
Achieve Life Sciences |
Achieve Life Sciences Awarded Grant from the National Institutes of Health to Conduct Phase 2 Trial of Cytisinicline in Nicotine e-cigarette Users achievelifesciences.com ↗ |
| 2022-04-27 |
Achieve Life Sciences |
Achieve Life Sciences Announces Successful, Statistically Significant Smoking Cessation Results in Phase 3 ORCA-2 Clinical Trial of Cytisinicline in Adult Smokers achievelifesciences.com ↗ |
| 2022-03-15 |
Achieve Life Sciences |
Achieve Life Sciences Announces Cytisinicline Presentation at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting achievelifesciences.com ↗ |
| 2022-02-03 |
Achieve Life Sciences |
Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Award achievelifesciences.com ↗ |
| 2022-01-25 |
Achieve Life Sciences |
Achieve Life Sciences Announces Initiation of the Phase 3 ORCA-3 Clinical Trial Evaluating Cytisinicline for Smoking Cessation achievelifesciences.com ↗ |
| 2022-01-04 |
Achieve Life Sciences |
Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking Cessation achievelifesciences.com ↗ |
| 2021-12-22 |
Achieve Life Sciences |
Achieve Life Sciences Announces $25 Million Loan Facility from Silicon Valley Bank to Fund Cytisinicline Smoking Cessation Clinical Development achievelifesciences.com ↗ |
| 2021-11-22 |
Achieve Life Sciences |
Achieve Life Sciences Announces Phase 3 ORCA-2 Trial of Cytisinicline in Smoking Cessation Clears Final Review by Data Safety Monitoring Committee (DSMC) achievelifesciences.com ↗ |
| 2021-11-09 |
Achieve Life Sciences |
Achieve Reports Financial Results for Third Quarter 2021 and Provides Update on Cytisinicline Development achievelifesciences.com ↗ |
| 2021-11-02 |
Achieve Life Sciences |
Achieve Life Sciences Announces FDA Acceptance of IND Application for Cytisinicline’s Second Planned Indication for Nicotine E-cigarette Cessation achievelifesciences.com ↗ |
| 2021-09-14 |
Achieve Life Sciences |
Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual Conference achievelifesciences.com ↗ |
| 2021-08-13 |
Achieve Life Sciences |
Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Awards achievelifesciences.com ↗ |
| 2021-08-11 |
Achieve Life Sciences |
Achieve Announces Two Patents Granted by USPTO for Novel Cytisinicline Dosing and Administration Regimen achievelifesciences.com ↗ |
| 2021-07-22 |
Achieve Life Sciences |
Achieve Life Sciences Awarded Grant from the National Institutes of Health (NIH) for the Evaluation of Cytisinicline in Cessation of Nicotine E-cigarette Use achievelifesciences.com ↗ |
| 2021-06-29 |
Achieve Life Sciences |
Achieve Announces Completion of Target Enrollment of 750 Subjects in Phase 3 ORCA-2 Smoking Cessation Trial of Cytisinicline achievelifesciences.com ↗ |
| 2021-06-03 |
Achieve Life Sciences |
Achieve Announces Allowance of U.S. Patents for Dosing and Administration of Cytisinicline for the Treatment and Prevention of Addiction achievelifesciences.com ↗ |
| 2021-04-14 |
Achieve Life Sciences |
Achieve Announces Publication of the ORCA-1 Phase 2b Clinical Trial of Cytisinicline in Adult Smokers in Nicotine and Tobacco Research achievelifesciences.com ↗ |
| 2021-03-25 |
Achieve Life Sciences |
Achieve Announces Publication of the RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix(R) (varenicline) in Addiction achievelifesciences.com ↗ |
| 2020-11-12 |
Achieve Life Sciences |
Achieve Reports Financial Results for Third Quarter 2020 and Provides Corporate and Cytisinicline Development Update achievelifesciences.com ↗ |
| 2020-10-07 |
Achieve Life Sciences |
Achieve Life Sciences Announces Start of Phase 3 ORCA-2 Clinical Trial Evaluating Cytisinicline for Smoking Cessation achievelifesciences.com ↗ |
| 2020-09-18 |
Achieve Life Sciences |
Achieve Life Sciences Announces Results from Evaluation of Cytisinicline (cytisine) versus Chantix® (varenicline) in 5-HT3 Receptor Binding Assay Study achievelifesciences.com ↗ |
| 2020-09-18 |
Achieve Life Sciences |
Achieve Announces Presentation of Investigator-Led RAUORA Trial Data Demonstrating Significantly Fewer Side Effects with Higher Quit Rates for Cytisinicline (cytisine) Compared to Chantix® (varenicline) in First Head-to-Head Comparative Study achievelifesciences.com ↗ |
| 2020-09-10 |
Achieve Life Sciences |
Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 20th Annual Society for Research on Nicotine & Tobacco Europe (SRNT-E) Virtual Conference achievelifesciences.com ↗ |
| 2020-08-06 |
Achieve Life Sciences |
Achieve Reports Financial Results for Second Quarter 2020 and Provides Update on Cytisinicline Development Program achievelifesciences.com ↗ |
| 2020-07-31 |
Achieve Life Sciences |
Achieve Announces Patent Granted in the U.S. for Novel Analogs of Cytisinicline for Use in CNS and Addiction Indications achievelifesciences.com ↗ |
| 2020-06-29 |
Achieve Life Sciences |
Achieve Announces Successful Results from the Investigator-Initiated RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix® (varenicline) as a Treatment to Quit Smoking achievelifesciences.com ↗ |
| 2020-05-14 |
Achieve Life Sciences |
Achieve Reports Financial Results for First Quarter 2020 and Provides Update on Cytisinicline Development Program achievelifesciences.com ↗ |
| 2020-03-13 |
Achieve Life Sciences |
Achieve Reports Financial Results for Fourth Quarter and Year-End 2019 and Provides Update on Cytisinicline Development Program achievelifesciences.com ↗ |
| 2020-03-12 |
Achieve Life Sciences |
Achieve Life Sciences Announces Presentation of Additional Cytisinicline Analyses at the Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting achievelifesciences.com ↗ |
| 2020-02-06 |
Achieve Life Sciences |
Achieve Life Sciences Announces Agreement with the FreeMind Group to Assist in Securing Non-Dilutive Funding to Evaluate Cytisinicline in Vaping and e-Cigarette Users achievelifesciences.com ↗ |
| 2019-12-09 |
Achieve Life Sciences |
Achieve Life Sciences Announces Completion of Meeting with the U.S. Food & Drug Administration (FDA) on Cytisinicline Smoking Cessation Phase 3 Clinical Development Program achievelifesciences.com ↗ |
| 2019-11-06 |
Achieve Life Sciences |
Achieve Reports Financial Results for Third Quarter 2019 and Provides Update on Cytisinicline Development Program achievelifesciences.com ↗ |
| 2019-10-24 |
Achieve Life Sciences |
Achieve Life Sciences Announces Presentation of Cytisinicline Data at Society for Research on Nicotine & Tobacco Oceania (SRNT-O) Inaugural Conference achievelifesciences.com ↗ |
| 2019-08-08 |
Achieve Life Sciences |
Achieve Reports Financial Results for Second Quarter 2019 and Provides Cytisinicline Clinical Development Update achievelifesciences.com ↗ |
| 2019-07-23 |
Achieve Life Sciences |
Achieve Life Sciences Extends Collaboration with the National Institutes of Health to Advance the Development of Cytisinicline for Smoking Cessation achievelifesciences.com ↗ |
| 2019-06-11 |
Achieve Life Sciences |
Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial achievelifesciences.com ↗ |
| 2019-05-30 |
Achieve Life Sciences |
Achieve Announces Patent Granted in the U.S. for Novel Formulation of Cytisinicline achievelifesciences.com ↗ |
| 2019-05-15 |
Achieve Life Sciences |
Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update achievelifesciences.com ↗ |
| 2019-04-24 |
Achieve Life Sciences |
Achieve Life Sciences Announces Last Subject, Last Visit Completed in Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation achievelifesciences.com ↗ |
| 2019-04-02 |
Achieve Life Sciences |
Achieve Life Sciences Announces Successful Completion of the Second and Final DSMC Review of Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation achievelifesciences.com ↗ |
| 2019-03-14 |
Achieve Life Sciences |
Achieve Reports Financial Results for Year-End 2018 and Provides Cytisinicline Clinical Development Update achievelifesciences.com ↗ |
| 2019-02-22 |
Achieve Life Sciences |
Achieve Announces Final Data from Cytisinicline Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study to be Presented at Society for Research on Nicotine & Tobacco Annual Meeting achievelifesciences.com ↗ |
| 2019-02-20 |
Achieve Life Sciences |
Achieve Life Sciences Announces Completion of Enrollment in 254-Subject Phase 2b Trial of Cytisinicline for Smoking Cessation achievelifesciences.com ↗ |
| 2018-12-18 |
Achieve Life Sciences |
Achieve Announces Update on Cytisinicline Clinical Development Program achievelifesciences.com ↗ |
| 2018-11-07 |
Achieve Life Sciences |
Achieve Reports Financial Results for Third Quarter 2018 and Provides Cytisinicline (Cytisine) Clinical Development Update achievelifesciences.com ↗ |
| 2018-10-30 |
Achieve Life Sciences |
Achieve Life Sciences Announces Initiation of Phase 2b ORCA-1 Trial Evaluating Cytisinicline (cytisine) for Smoking Cessation achievelifesciences.com ↗ |
|